Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|March 3, 2007
Safety and efficacy of a recombinant hepatitis E vaccineMrigendra Prasad Shrestha, Robert McNair Scott, Durga Man Joshi, et al.
Vaccine|November 18, 2021
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing ageKulkanya Chokephaibulkit, Thanyawee Puthanakit, Niranjan Bhat, et al.
The Lancet. Infectious Diseases|April 24, 2022
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trialNicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, et al.
Vaccines|November 26, 2024
Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and ConsiderationsDarin Zehrung, Bruce L Innis, Auliya A Suwantika, et al.
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
Vaccines|November 11, 2022
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population ImmunityMin Z Levine, Crystal Holiday, Yaohui Bai, et al.
BMC Infectious Diseases|April 20, 2018
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adultsCarine Claeys, Mamadou Drame, José García-Sicilia, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2015
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto RicoKristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, et al.
Journal of the Pediatric Infectious Diseases Society|January 8, 2017
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled TrialVarsha K Jain, Joseph B Domachowske, Long Wang, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|March 3, 2007
Safety and efficacy of a recombinant hepatitis E vaccineMrigendra Prasad Shrestha, Robert McNair Scott, Durga Man Joshi, et al.
Vaccine|November 18, 2021
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing ageKulkanya Chokephaibulkit, Thanyawee Puthanakit, Niranjan Bhat, et al.
The Lancet. Infectious Diseases|April 24, 2022
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trialNicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, et al.
Vaccines|November 26, 2024
Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and ConsiderationsDarin Zehrung, Bruce L Innis, Auliya A Suwantika, et al.
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
Vaccines|November 11, 2022
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population ImmunityMin Z Levine, Crystal Holiday, Yaohui Bai, et al.
BMC Infectious Diseases|April 20, 2018
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adultsCarine Claeys, Mamadou Drame, José García-Sicilia, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2015
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto RicoKristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, et al.
Journal of the Pediatric Infectious Diseases Society|January 8, 2017
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled TrialVarsha K Jain, Joseph B Domachowske, Long Wang, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
Pageof 12